dfda compounded glp-1 receptor agonists Pharmacovigilance Assessment of Agonists: Insights From the FDA Adverse Event Reporting System FDA is moving to restrict

The majority of T2D management is in primary care, where clinicians (medical, nursing and pharmacist staff) play an important role in addressing patient needs and achieving treatment goals

The findings from two clinical trials suggest that a lower dose of GLP-1 drugs, or switching to an oral pill like Foundayo, can help to maintain weight loss.

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.

In clinical practice, drug selection should therefore prioritize factors such as tolerability, safety profile, adherence, cost, and patient preference rather than expecting major differences in cardiovascular efficacy.